MX2019013643A - Terapia de combinacion de 7-bencil-10-(2-metilbencil)-2,6,7,8,9,10 -hexahidroimidazo[1,2-a]pirido [4,3-d]pirimidin-5(3h)-ona. - Google Patents

Terapia de combinacion de 7-bencil-10-(2-metilbencil)-2,6,7,8,9,10 -hexahidroimidazo[1,2-a]pirido [4,3-d]pirimidin-5(3h)-ona.

Info

Publication number
MX2019013643A
MX2019013643A MX2019013643A MX2019013643A MX2019013643A MX 2019013643 A MX2019013643 A MX 2019013643A MX 2019013643 A MX2019013643 A MX 2019013643A MX 2019013643 A MX2019013643 A MX 2019013643A MX 2019013643 A MX2019013643 A MX 2019013643A
Authority
MX
Mexico
Prior art keywords
hexahydroimidazo
pyrido
methylbenzyl
pyrimidin
benzyl
Prior art date
Application number
MX2019013643A
Other languages
English (en)
Inventor
S Pottorf Richard
Rao Nallaganchu Bhaskara
L Olson Gary
Stogniew Martin
E Allen Joshua
Original Assignee
Oncoceutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncoceutics Inc filed Critical Oncoceutics Inc
Publication of MX2019013643A publication Critical patent/MX2019013643A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Esta descripción se refiere, al menos en parte, a un método de tratamiento. En una modalidad, el método de tratamiento comprende administrar a un sujeto con la necesidad de dicho tratamiento un primer agente terapéutico que incluye compuesto (1); o una sal farmacéuticamente aceptable del mismo en combinación con un segundo agente terapéutico, en donde el primer agente terapéutico y el segundo agente terapéutico se administran ya sea simultánea o secuencialmente.
MX2019013643A 2013-03-13 2015-09-11 Terapia de combinacion de 7-bencil-10-(2-metilbencil)-2,6,7,8,9,10 -hexahidroimidazo[1,2-a]pirido [4,3-d]pirimidin-5(3h)-ona. MX2019013643A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361779828P 2013-03-13 2013-03-13
US201361904718P 2013-11-15 2013-11-15

Publications (1)

Publication Number Publication Date
MX2019013643A true MX2019013643A (es) 2020-02-03

Family

ID=51527915

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015012636A MX2015012636A (es) 2013-03-13 2014-03-13 Terapia de combinacion de 7-bencil-10-(2-metilbencil)-2,6,7,8,9,10 -hexahidroimidazol[1,2-a] pirido [4,3-d] pirimidin-5(3h)-ona.
MX2019013643A MX2019013643A (es) 2013-03-13 2015-09-11 Terapia de combinacion de 7-bencil-10-(2-metilbencil)-2,6,7,8,9,10 -hexahidroimidazo[1,2-a]pirido [4,3-d]pirimidin-5(3h)-ona.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015012636A MX2015012636A (es) 2013-03-13 2014-03-13 Terapia de combinacion de 7-bencil-10-(2-metilbencil)-2,6,7,8,9,10 -hexahidroimidazol[1,2-a] pirido [4,3-d] pirimidin-5(3h)-ona.

Country Status (26)

Country Link
US (1) US9265765B2 (es)
EP (2) EP2968294B1 (es)
JP (3) JP6446025B2 (es)
KR (2) KR102438135B1 (es)
CN (1) CN105530937A (es)
AU (3) AU2014244117B2 (es)
BR (1) BR112015023256A2 (es)
CA (2) CA3204801A1 (es)
CY (1) CY1121735T1 (es)
DK (1) DK2968294T3 (es)
EA (1) EA037937B1 (es)
ES (1) ES2734568T3 (es)
HK (1) HK1217653A1 (es)
HR (1) HRP20191181T1 (es)
HU (1) HUE044238T2 (es)
IL (2) IL241452B (es)
LT (1) LT2968294T (es)
ME (1) ME03470B (es)
MX (2) MX2015012636A (es)
NZ (2) NZ711948A (es)
PL (1) PL2968294T3 (es)
PT (1) PT2968294T (es)
RS (1) RS59013B1 (es)
SG (2) SG10201808496VA (es)
SI (1) SI2968294T1 (es)
WO (1) WO2014160130A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3679934B1 (en) 2011-04-29 2024-06-05 The Penn State Research Foundation Small molecule trail gene induction by normal and tumor cells as an anticancer therapy
EP2968294B1 (en) 2013-03-13 2019-05-01 Oncoceutics, Inc. 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-on for use in the treatment of cancer
US9376437B2 (en) 2013-03-13 2016-06-28 Oncoceutics, Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
SI2970473T1 (sl) 2013-03-14 2017-10-30 Bristol-Myers Squibb Company Kombinacija dr5 agonista in anti-pd-1 antagonista in postopek uporabe
US9394365B1 (en) 2014-03-12 2016-07-19 Yeda Research And Development Co., Ltd Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
US10144778B2 (en) 2014-03-12 2018-12-04 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US10618963B2 (en) 2014-03-12 2020-04-14 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
EP3662910A1 (en) * 2014-03-31 2020-06-10 The Scripps Research Institute Pharmacophore for trail induction
MD3250208T2 (ro) * 2015-01-30 2021-02-28 Oncoceutics Inc 7-Benzil-4-(4-(trifluorometil)benzil)-1,2,6,7,8,9-hexahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(1h)-onă și sărurile acesteia și utilizarea lor în terapie
CN104860948B (zh) * 2015-05-15 2017-09-26 南京盖特医药技术有限公司 咪唑并嘧啶酮类化合物及其制备方法和应用
EP3385395B9 (en) * 2015-08-17 2020-05-20 Kura Oncology, Inc. Methods of treating cancer patients with farnesyl transferase inhibitors
KR20170037260A (ko) 2015-09-25 2017-04-04 현대자동차주식회사 차량용 배터리 시스템 및 그 제어 방법
SG10202108306UA (en) 2016-01-29 2021-08-30 Oncoceutics Inc G protein-coupled receptor (gpcr) modulation by imipridones
PE20181953A1 (es) 2016-03-02 2018-12-17 Eisai Randd Man Co Ltd Conjugados de anticuerpo y farmaco basados en eribulina y metodos para su uso
KR20170110520A (ko) * 2016-03-23 2017-10-11 고려대학교 산학협력단 mTOR 억제제 및 N-아세틸시스테인을 포함하는 간섬유화 억제용 조성물
JP2019513828A (ja) 2016-04-06 2019-05-30 ノクソファーム リミティド 改善された薬物動態を有するイソフラボノイド組成物
WO2017173496A1 (en) * 2016-04-06 2017-10-12 Noxopharm Limited Radiotherapy improvements
AU2017310526B2 (en) * 2016-08-12 2021-08-12 Edwin J. Iwanowicz Protein kinase regulators
WO2018085518A2 (en) 2016-11-03 2018-05-11 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
WO2018129080A1 (en) * 2017-01-04 2018-07-12 The Board Of Trustees Of The Leland Stanford Junior University Target genes in myc-driven neoplasia
ES2928773T3 (es) 2017-01-17 2022-11-22 Heparegenix Gmbh Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos
US10172862B2 (en) 2017-01-30 2019-01-08 Oncoceutics, Inc. Imipridones for gliomas
IT201800004082A1 (it) * 2018-03-29 2019-09-29 Berlin Chemie Ag Composizioni farmaceutiche antitumorali per terapia combinata
US20200046703A1 (en) * 2018-08-09 2020-02-13 Asymmetric Therapeutics, Llc Compositions and methods for treatment of the side-effects associated with administration of therapeutic agents
US11633399B2 (en) 2018-12-25 2023-04-25 Sol-Gel Technologies Ltd. Treatment of skin disorders with compositions comprising an EGFR inhibitor
WO2020147842A1 (zh) * 2019-01-18 2020-07-23 南京明德新药研发有限公司 吡啶并嘧啶类化合物在制备治疗鼻咽癌药物中的应用
EP3725370A1 (en) 2019-04-19 2020-10-21 ImmunoBrain Checkpoint, Inc. Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
EP4066837A4 (en) * 2019-11-28 2023-12-06 Inxmed (Nanjing) Co., Ltd. USE OF BI853520 IN THE TREATMENT OF CANCER
AU2021247415A1 (en) 2020-03-30 2022-09-29 Noxopharm Limited Methods for the treatment of inflammation associated with infection
CN117599041B (zh) * 2024-01-22 2024-05-03 中国人民解放军军事科学院军事医学研究院 去氢雌马酚及其衍生物作为新型辐射防护剂和细胞保护剂的医药用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2150062A1 (de) * 1971-10-07 1973-04-12 Boehringer Sohn Ingelheim Imidazo- eckige klammer auf 1,2-a eckige klammer zu -pyrido- eckige klammer auf 4,3-d eckige klammer zu -pyrimidine, deren saeureadditionssalze und verfahren zu deren herstellung
US4642345A (en) 1980-08-14 1987-02-10 Mead Johnson & Company 6,7-dihydro-3H-imidazo[1,2-a]-purine-9(4H)-ones
US7635690B2 (en) 1999-01-22 2009-12-22 Emory University HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
AU2003217961B2 (en) 2002-03-08 2008-02-28 Signal Pharmaceuticals, Llc Combination therapy for treating, preventing or managing proliferative disorders and cancers
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
CN105288630A (zh) 2005-02-18 2016-02-03 阿布拉科斯生物科学有限公司 治疗剂的组合和给予方式以及联合治疗
US20080221135A1 (en) 2005-05-13 2008-09-11 Bristol-Myers Squibb Company Combination therapy
JP2012502994A (ja) 2008-09-22 2012-02-02 アムジエン・インコーポレーテツド 治療方法
EP2367425B1 (en) 2008-12-11 2018-02-28 Abraxis BioScience, LLC Combination therapy including a taxane and a further therapeutic agent
US9724337B2 (en) 2009-04-21 2017-08-08 University Of Kentucky Research Foundation AG-205 for the treatment of breast cancer
DE102010014426A1 (de) * 2010-04-01 2011-10-06 Bayer Schering Pharma Aktiengesellschaft Verwendung neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren
EP3679934B1 (en) * 2011-04-29 2024-06-05 The Penn State Research Foundation Small molecule trail gene induction by normal and tumor cells as an anticancer therapy
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
EP2968294B1 (en) 2013-03-13 2019-05-01 Oncoceutics, Inc. 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-on for use in the treatment of cancer
EP3662910A1 (en) 2014-03-31 2020-06-10 The Scripps Research Institute Pharmacophore for trail induction

Also Published As

Publication number Publication date
EP2968294B1 (en) 2019-05-01
JP2016512563A (ja) 2016-04-28
AU2014244117B2 (en) 2018-12-20
SG11201507247WA (en) 2015-10-29
CA3204801A1 (en) 2014-10-02
RS59013B1 (sr) 2019-08-30
EA037937B1 (ru) 2021-06-09
DK2968294T3 (da) 2019-07-15
AU2014244117A1 (en) 2015-10-08
EP2968294A4 (en) 2016-10-19
HK1217653A1 (zh) 2017-01-20
CA2905037C (en) 2023-08-29
AU2020233606A1 (en) 2020-10-01
PT2968294T (pt) 2019-07-19
NZ751509A (en) 2023-03-31
EP2968294A1 (en) 2016-01-20
JP2020172510A (ja) 2020-10-22
CY1121735T1 (el) 2020-07-31
KR20220123335A (ko) 2022-09-06
PL2968294T3 (pl) 2019-10-31
ES2734568T3 (es) 2019-12-10
HRP20191181T1 (hr) 2019-10-04
US9265765B2 (en) 2016-02-23
AU2019201896A1 (en) 2019-04-11
US20140271540A1 (en) 2014-09-18
KR20150136602A (ko) 2015-12-07
IL241452B (en) 2020-07-30
JP6446025B2 (ja) 2018-12-26
ME03470B (me) 2020-01-20
EA201591715A1 (ru) 2016-07-29
HUE044238T2 (hu) 2019-10-28
SI2968294T1 (sl) 2019-08-30
LT2968294T (lt) 2019-07-25
IL275623A (en) 2020-08-31
WO2014160130A1 (en) 2014-10-02
SG10201808496VA (en) 2018-10-30
EP3572083A1 (en) 2019-11-27
JP2018184411A (ja) 2018-11-22
CA2905037A1 (en) 2014-10-02
KR102438135B1 (ko) 2022-08-29
IL241452A0 (en) 2015-11-30
MX2015012636A (es) 2017-02-06
NZ711948A (en) 2020-02-28
BR112015023256A2 (pt) 2017-07-18
CN105530937A (zh) 2016-04-27

Similar Documents

Publication Publication Date Title
MX2019013643A (es) Terapia de combinacion de 7-bencil-10-(2-metilbencil)-2,6,7,8,9,10 -hexahidroimidazo[1,2-a]pirido [4,3-d]pirimidin-5(3h)-ona.
MX2022001966A (es) 7-bencil-4-(2-metilbencil)-2,4,6,7,8,9- hexahidroimidazo[1,2-a]pir ido[3,4-e]pirimidin-5(1h)-ona, sales de la misma y metodos de uso.
MX2023000782A (es) 7-bencil-4-(2-metilbencilo)-2,4,6,7,8,9-hexahidroimidazo [1,2-a]pirido[3,4-e]pirimidin-5(1h)-ona, analogos y sales del mismo y su uso en terapia.
IL257748B (en) Derivatives of pyrazole [4,3-b]pyridine, pyrazolo[4,3-b]pyridine and pyrazolo[4,3-b]pyrazine for use in the treatment of cancer, inflammatory diseases and neurodegenerative diseases,
EA201991877A2 (ru) 7-бензил-4-(2-метилбензил)-2,4,6,7,8,9-гексагидроимидазо[1,2-a]пиридо[3,4-e]пиримидин-5(1h)-он, его соли и способы применения
PH12018502134A1 (en) Methods of treating pediatric cancers
WO2014186388A3 (en) Administration of nedd8-activating enzyme inhibitor and chemotherapeutic agents